Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
01/10/2026 06:15
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Oct 1 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it would pay US partner Regeneron REGN.O $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.
The companies said they had settled earlier litigation over the collaboration and that they would split costs and profits of the expanded partnership equally.
(Reporting by Hugo Lhomedet in Gdansk, editing by Milla Nissi-Prussak)
Recent news on Sanofi SA
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
EdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments